Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma

doi:10.16352/j.issn.1001-6325.2022.12.1930

Basic & Clinical Medicine ›› 2022, Vol. 42 ›› Issue (12): 1930-1934.doi: 10.16352/j.issn.1001-6325.2022.12.1930

• Mini Reviews • Previous Articles Next Articles

Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma

WANG Yu-min¹, CHEN Ji-chao^1*, WANG Hong-quan², WANG Jin-hua³, TANG Bo²

1. Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing 100049;
2. Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060;
3. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, CAMS & PUMC, Beijing Key Laboratory of Drug Target and Screening Research, Beijing 100050,China

Received:2021-05-11 Revised:2021-12-31 Online:2022-12-05 Published:2022-11-23
Contact: ^* chen_htzxyy@sina.com

Abstract

Abstract: Metabolic reprogramming is considered to be one of the top characteristics of tumor cells. Ample experimental studies have shown that microRNAs, which are a group of multifunctional non-coding RNAs, play an important role in the development of hepatocellular carcinoma (HCC) through lipid metabolic reprogramming. The current review briefly introduces the recent progress of specific microRNAs targeting at lipid metabolic reprogramming in HCC, which may provide a potential strategy for clinical targeting tumor therapy.

Key words: hepatocellular carcinoma, microRNAs, lipid metabolic reprogramming, tumorigenesis

CLC Number:

R735.7

WANG Yu-min, CHEN Ji-chao, WANG Hong-quan, WANG Jin-hua, TANG Bo. Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma[J]. Basic & Clinical Medicine, 2022, 42(12): 1930-1934.

References 14

[1]	Nakagawa H, Hayata Y, Kawamura S, et al. Lipid metabolic reprogramming in hepatocellular carcinoma[J]. Cancers (Basel), 2018,10:447.doi: 10.3390/cancers10110447.
[2]	Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight[J]. Nat Rev Cancer, 2013,13:227-232.
[3]	Budhu A, Roessler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes[J]. Gastroenterology, 2013,144:1066-1075.
[4]	Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells[J]. Oncogenesis, 2016,5:e189.doi: 10.1038/oncsis.2015.49.
[5]	Mosaoa R, Kasprzyk-Pawelec A, Fernandez HR, et al. The mitochondrial citrate carrier SLC25A1/CIC and the fundamental role of citrate in cancer, Inflammation and Beyond[J]. Biomolecules, 2021,11:141.doi: 10.3390/biom11020141.
[6]	Zhao G, Dong L, Shi H, et al. MicroRNA-1207-5p inhibits hepatocellular carcinoma cell growth and invasion through the fatty acid synthase-mediated Akt/mTOR signalling pathway[J]. Oncol Rep, 2016,36:1709-1716.
[7]	Wu H, Ng R, Chen X, et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway[J]. Gut, 2016,65:1850-1860.
[8]	Zhang H, Feng Z, Huang R, et al. MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1[J]. Int J Oncol, 2014,45:2143-2152.
[9]	Li H, Chen Z, Zhang Y, et al. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis[J]. Cancer Lett, 2021,519:161-171.
[10]	Lin YX, Wu XB, Zheng CW, et al. Mechanistic investigation on the regulation of FABP1 by the IL-6/miR-603 signaling in the pathogenesis of hepatocellular carcinoma[J]. Biomed Res Int, 2021:8579658.doi: 10.1155/2021/8579658.
[11]	Bai PS, Xia N, Sun H, et al. Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipo-genesis in HBV-related hepatocellular carcinoma[J]. J Cell Mol Med, 2017,21:3023-3043.
[12]	Zare M, Panahi G, Koushki M, et al. Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b[J]. Arch Physiol Biochem, 2022,128:333-340.
[13]	Yuan P, Mu J, Wang Z, et al. Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation[J]. Cell Death Dis, 2021,12:361.doi:10.1038/s41419-021-03648-1.
[14]	Liu Y, Lu LL, Wen D, et al. MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming[J]. J Hematol Oncol, 2020,13:12.doi: 10.1186/s13045-019-0841-3.

[1]	LI Shunle, LI Rong, TIAN Yaya, RAN Xiaoli, ZHAO Yanpei, XU Meng. Association of serum KLF5 and actinin-4 levels with prognosis of TACE treatment for hepatocellular carcinoma [J]. Basic & Clinical Medicine, 2024, 44(9): 1284-1289.
[2]	NAN Lu, GUO Menjie, GAO Yanan, JIA Hongyan. Research progress on the mechanism of annexin A family members in breast cancer [J]. Basic & Clinical Medicine, 2024, 44(3): 393-397.
[3]	LU Huiying, WANG Jianguo. Downregulation of demethylase FTO inhibits proliferation of human liver cancer cell line HepG2 [J]. Basic & Clinical Medicine, 2024, 44(2): 185-191.
[4]	Yimamaimaitijiang·ABRA, Pakhardin·BAIKERE, YI Chao, TONG Qing. Clinical value of plasma hsa_circ_005230 in the diagnosis and prognosis evaluation of primary hepatocellular carcinoma [J]. Basic & Clinical Medicine, 2023, 43(9): 1417-1422.
[5]	LIN Yingxue, CUI Haipeng, WANG Aiguo, YAO Yinhui, ZHAO Juan. Rapamycin alleviates hepatocellular carcinoma progressing in transgenic mice [J]. Basic & Clinical Medicine, 2023, 43(8): 1241-1246.
[6]	ZOU Jin, HE Xianglei, ZHANG Xin, CHEN Riping, ZHANG Yu, HU Shuaiyue, YING Shibo. Expression of chemical modification enzymes PADs and PRMTs targeting protein arginine residues in human hepatocellular carcinoma cell lines [J]. Basic & Clinical Medicine, 2023, 43(6): 898-903.
[7]	JI Mengdie, YUAN Zan, BIAN Xiaocui, YANG Yurong, GUO Xin, WANG Qi, CHEN Yang. Analysis of genomic copy number variations in human hepatocellular carcinoma cell lines HepG2 and Huh7 [J]. Basic & Clinical Medicine, 2023, 43(6): 960-966.
[8]	ZHANG Yanping, YAO Liuxu, DING Qiannan, HUANG Zeyong, LI Yuhong, HUANG Suqin. Influencing factors and the clinical significance of tumorigenesis rate in PDX model of colorectal cancer [J]. Basic & Clinical Medicine, 2023, 43(4): 596-602.
[9]	YANG Mengdi, DING Yulu, WANG Yujie, HE Fengying, SUN Linnan, ZHEN Donghu. Research progress on the role of microRNA in diabetic osteoporosis [J]. Basic & Clinical Medicine, 2023, 43(2): 311-316.
[10]	LIU Aixia, ZHANG Hao, SUN Jie, YANG Lihua, ZHAO Xiaotao. The role of GPS2 in regulating proliferation, migration and invasion of hepatocellular carcinoma cell line MHCC-97H [J]. Basic & Clinical Medicine, 2023, 43(12): 1784-1791.
[11]	CHA Na, HAO Dandan, LI Tianzhu. Research progress of microRNAs suppressing tumorigenesis through Hippo signaling [J]. Basic & Clinical Medicine, 2023, 43(12): 1871-1875.
[12]	HUANG Yisheng, YE Qiwen, WANG Jingfeng. miR-203a-3p inhibits proliferation of human hepatocellular carcinoma cell lines [J]. Basic & Clinical Medicine, 2023, 43(1): 87-94.
[13]	ZHOU Lan, ZHANG Sheng-gui, HU Zu-liang, WANG Tian-xian, YUE Peng-peng, YU Hong-hao. Efficient editing of mouse miR let-7a based on CRISPR/Cas9 system [J]. Basic & Clinical Medicine, 2022, 42(6): 857-863.
[14]	ZHAO Yu-shan, JI Meng-die, DONG Yu-cheng, GUO Xin, SONG Bo-yuan, CHEN Yang. Epigenetic regulation mechanism of EZH2 gene in hepatocellular carcinoma [J]. Basic & Clinical Medicine, 2022, 42(6): 864-870.
[15]	HUANG Rong, ZHANG Jian, CHE Xu. Effect of SLC4A10 expression on prognosis of patient with hepatocellular carcinoma [J]. Basic & Clinical Medicine, 2022, 42(3): 461-466.

Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References 14

Related Articles 15

Recommended Articles

Metrics

Comments